Suramin is a polysulfonated naphthylurea currently investigated for the treatment of
advanced malignancy. We have previously reported that suramin was a potent inducer of …

Suramin is an anti‐cancer drug which induces the differentiation of the human colon cancer
clone HT29‐D4. Yet chronic suramin treatment of these cells eventually leads to a marked …

Suramin is a polyanionic compound currently used under evaluation for antineoplastic
activity. One of the main problems encountered during clinical trials was an adverse …

Suramin, a polysulfonated naphtylurea, has been shown to bind to a wide variety of tumor
growth factors, and to exhibit anti‐proliferative effects on several cell lines. We have followed …

Suramin is a polysulfonated compound currently under investigation for the treatment of
various types of cancer. Pharmacokinetic studies from clinical trials in humans have shown …

Suramin, a polysulfonated naphthylurea, is currently under investigation for treatment of
advanced malignancy and has been shown to exhibit antiproliferative effects on some cells …

Background: Suramin is a polysulfonated urea recently tested in clinical trials as an
anticancer agent. Purpose: To define tumor types for further clinical testing of suramin, we …

Suramin, a drug currently used for advanced malignancy, induces the differentiation of the
human colonic adenocarcinoma cell clone HT29-D4 and this process is correlated with a …

Suramin is a polysulfonated compound originally developed nearly 75 years ago for use as
a trypanocidal agent. Recent studies indicate that suramin can also disrupt mammalian cell …

Suramin is a polysulphonated naphthylurea currently investigated for the treatment of
advanced malignancy. In the present study, we have analysed the uptake and the …